You are here

  • Home
  • Archive
  • Volume 25, Issue 7
  • Evaluation of the Hematologic Safety of Same Day Versus Standard Administration (24- to 72-Hour Delay) of Pegfilgrastim in Gynecology Oncology Patients Undergoing Cytotoxic Chemotherapy

Citation Tools

Article menu
Download PDFPDF
Quality of Life
Evaluation of the Hematologic Safety of Same Day Versus Standard Administration (24- to 72-Hour Delay) of Pegfilgrastim in Gynecology Oncology Patients Undergoing Cytotoxic Chemotherapy

Download to a citation manager

Download the citation for this article by clicking on one of the following citation managers:

Cite this article as:
Billingsley CC, Jacobson SN, Crafton SM, et al
Evaluation of the Hematologic Safety of Same Day Versus Standard Administration (24- to 72-Hour Delay) of Pegfilgrastim in Gynecology Oncology Patients Undergoing Cytotoxic Chemotherapy
International Journal of Gynecologic Cancer 2015;25:1331-1336.